Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo

16 Apr 2025

Abstract excerpt

BACKGROUND: Tecovirimat is available for the treatment of mpox (formerly known as monkeypox) in Europe and the United States, on the basis of findings from efficacy studies in animals and safety evaluations in healthy humans. Evidence from randomized, controlled trials of safety and efficacy in patients with mpox is lacking. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of tecovirimat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Poxvirus research and outbreaks
Share to Herpesvirus Infections and Treatments
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40239067
DOI: 10.1056/nejmoa2412439

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of CongoPMID 40239067Read ↗

Monkeypox Virus Shedding Despite Tecovirimat Treatment in a Cohort in Toronto, Canada.Semantic proximity Read ↗

Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024.Semantic proximity Read ↗

A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox OutbreakSemantic proximity Read ↗

Mpox: current knowledge and understanding—a scoping reviewSemantic proximity Read ↗

Notes from the Field: Clade II Mpox Surveillance Update — United States, October 2023–April 2024Semantic proximity Read ↗

The evolving mpox threat (2022-2024): clade dynamics, immune evasion, and escalating global health challenges.Semantic proximity Read ↗

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023Semantic proximity Read ↗

Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreakSemantic proximity Read ↗

Efficacy of Tecovirimat and Cidofovir Against MPXV-Induced Pneumonia, Skin Lesion, and Arthritis in the High-Risk Population-Relevant SCID Mouse ModelSemantic proximity Read ↗

Epidemiological and Clinical Features of Mpox during the Clade Ib Outbreak in South-Kivu, Democratic Republic of the Congo: a Prospective Cohort StudySemantic proximity Read ↗

Implications of the 2023–2024 MPXV clade I outbreak in the Democratic Republic of Congo to global public healthSemantic proximity Read ↗

Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: a study protocol for an Expanded Access ProgrammeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.